Management of inflammaging in kidney diseases: focusing on the current investigational drugs

Simple item page
dc.contributor.authorGaikwad, Anil Bhanudas
dc.date.accessioned2025-03-17T04:39:21Z
dc.date.available2025-03-17T04:39:21Z
dc.date.issued2024-10
dc.description.abstractTo improve kidney disease treatments, it is crucial to understand how inflammaging affects patients´ longevity. We could potentially slow down kidney disease progression and enhance longevity by targeting specific pathways involved in inflammaging with potential drugs.en_US
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/13543784.2024.2417755
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18383
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.subjectPharmacyen_US
dc.subjectAutophagyen_US
dc.subjectCaloric restrictionen_US
dc.subjectInflammagingen_US
dc.subjectKidney diseasesen_US
dc.subjectMetabolic dysregulationen_US
dc.titleManagement of inflammaging in kidney diseases: focusing on the current investigational drugsen_US
dc.typeArticleen_US

Files

Collections

Department of Pharmacy